Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
314
-
Total 13F shares, excl. options
-
55.8M
-
Shares change
-
+5.14M
-
Total reported value, excl. options
-
$4.62B
-
Value change
-
+$425M
-
Put/Call ratio
-
0.13
-
Number of buys
-
165
-
Number of sells
-
-136
-
Price
-
$82.73
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q2 2024
357 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q2 2024.
HAEMONETICS CORP - Common Stock (HAE) has 314 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55.8M shares
.
Largest 10 shareholders include Capital Research Global Investors (6.92M shares), BlackRock Inc. (5.96M shares), VANGUARD GROUP INC (5.14M shares), WELLINGTON MANAGEMENT GROUP LLP (3.84M shares), NEUBERGER BERMAN GROUP LLC (3.83M shares), STATE STREET CORP (1.85M shares), T. Rowe Price Investment Management, Inc. (1.64M shares), FRANKLIN RESOURCES INC (1.42M shares), ROYCE & ASSOCIATES LP (1.18M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.17M shares).
This table shows the top 314 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.